Myopic choroidal neovascularization

Yoshida, Takeshi; Ohno‐Matsui, Kyoko; Yasuzumi, Kenjiro; Kojima, Ariko; Shimada, Noriaki; Futagami, Soh; Tokoro, Takashi; Mochizuki, Manabu

doi:10.1016/s0161-6420(03)00461-5

Cited by 309 publications

(226 citation statements)

References 24 publications

Supporting

Mentioning

215

Contrasting

Unclassified

Order By: Relevance

“…In the VIP trial, vPDT showed stabilization of disease with a median VA loss of À 1 letter at 6 months' time point compared with placebo (loss of 9 letters at 6-months) 9,10 Post hoc analysis in this study found that 98% of patients avoided the loss of eight or more letters at the 6 months' time point, which compares favourably to the VIP study primary end point data previously discussed. Thus, given the substantial risk of deterioration of vision over time in untreated patients with myopic CNV, 6 intravitreal ranibizumab appears to offer a substantial benefit and the potential for VA recovery. Nonetheless, these ranibizumab results remain preliminary and 12 months' data are required to confirm any ongoing benefit.…”

Section: Eyementioning

confidence: 99%

“…CNV is detectable in 4-11% of affected eyes 4 with pathological myopia and occurs predominantly in those younger than 50 years of age, with almost 90% of eyes developing severe visual loss (r20/200) after 5-10 years. 5,6 Furthermore, in patients with established myopic CNV in one eye, about a third will develop CNV in the fellow eye within 8 years, 7 which would lead to significant morbidity of the individual's binocular visual function in their productive years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

Tufail

Patel

Sivaprasad

et al. 2013

Eye

View full text Add to dashboard Cite

Aims To evaluate the efficacy and safety of intravitreal ranibizumab in patients with choroidal neovascularisation secondary to pathological myopia (myopic CNV). Data are from a pre-planned, 6-month interim analysis. Methods Phase II, open-label, single arm, multicentre, 12-month study, recruiting patients (aged Z18 years) with active primary or recurrent subfoveal or juxtafoveal myopic CNV, with a best-corrected visual acuity (BCVA) score of 24-78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the study eye and a diagnosis of high myopia of at least À 6 dioptres. Patients received 0.5 mg ranibizumab administered intravitreally to the study eye, followed by monthly injections given as needed (based on a predefined algorithm) for up to 11 months. Results At 6 months, mean BCVA improved from baseline by 12.2 letters, as did central macular thickness (in this interim analysis defined as a measure of either central subfield macular thickness or centre point macular thickness) from baseline by 108 mm in the 48 study eyes of 48 patients. Fewer patients had centre-involving intraretinal oedema (13.0% vs 91.5%), intraretinal cysts (10.9% vs 57.4%), or subretinal fluid (13.0% vs 66.0%) at 6 months than at baseline. Patients received a mean of 1.9 retreatments, were satisfied with ranibizumab treatment, and well being was maintained. No new safety signals were identified. Conclusions Results from the planned interim analysis support the role of ranibizumab in the treatment of myopic CNV, with excellent efficacy achieved with a low number of injections and few serious adverse events.

show abstract

Section: Eyementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

Tufail

Patel

Sivaprasad

et al. 2013

Eye

View full text Add to dashboard Cite

show abstract

“…21 Yoshida et al 21 have reported a natural history of visual acuity dropping from 70% of the eyes with 20/200 or better at the onset of CNV to 55% at 3 years and 11% at 5 years. The results of PDT do not seem to be entirely satisfactory, as has been previously reported by our group, with 28% of the patients younger than 55 years and 54% of those older than 55 years, losing two or more lines by the end of the first year of treatment.…”

Section: Discussionmentioning

confidence: 99%

Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results

Ruiz-Moreno

Gómez‐Ulla

Montero

et al. 2007

Eye

View full text Add to dashboard Cite

Aim To describe the anatomical and visual outcome of subfoveal and juxtafoveal choroidal neovascularization (CNV) in highly myopic eyes treated by intravitreal bevacizumab. Methods Prospective, nonrandomized, multicentric, interventional pilot study. Twenty-six highly myopic eyes from 25 patients with subfoveal and juxtafoveal CNV were treated by three monthly intravitreal injections with 1.25 mg bevacizumab. Patients were evaluated for best-corrected visual acuity (BCVA) and optical coherence tomography at baseline and then monthly. ) at month 6. Fifteen eyes were naïve for treatment and 11 eyes had been previously treated by photodynamic therapy (PDT) (average 2.5 PDT sessions). Leakage from CNV had ceased in all eyes at month 3 and CNV was still closed at month 6. Neither ocular nor systemic safety issues appeared during the follow-up. Conclusions Intravitreal bevacizumab seems to be an effective and safe therapeutic procedure to treat subfoveal and juxtafoveal CNV in highly myopic eyes. Further studies are required to verify the efficacy and usefulness of this therapy compared with established treatments for this condition.

show abstract

“…9,10,30 Deste modo, e tendo em conta os resultados não sustentados com a terapia fotodinâmica, os novos fármacos antiangiogénicos têm sido cada vez mais utilizados no tratamento de patologias que cursam com NVC, como é o caso da miopia patológica.…”

Section: Discussionunclassified

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

et al. 2014

View full text Add to dashboard Cite

Introduction: Choroidal neovascularization secondary to pathological myopia is one of the leading causes of irreversible central vision loss in younger patients. The purposes of our study is to evaluate the long-term results of antiangiogenic treatment, with ranibizumab and/or bevacizumab, in myopic choroidal neovascularization and define the predictive factors for visual and anatomic outcomes. Material and Methods:In this study were included 84 eyes from 81 patients with myopic choroidal neovascularization. Eighty-four (100%) eyes accomplish 12 months of follow-up, 67 (79.8%) 24 months, 54 (64.3%) 36 months, 29 (34.5%) 48 months, and 15 (16.7%) 60 months. We retrieved data related to best corrected visual acuity measured with ETDRS chart, foveal center thickness on optical coherence tomography and fluorescein angiographic findings, before and after treatment. Results:The best corrected visual acuity and foveal center thickness improvements were statistically significant for all follow-up times (p < 0.05). Mean baseline best corrected visual acuity was 43.7 ± 20.1 letters and mean baseline foveal center thickness was 304.8 ± 127.9µm. Mean best corrected visual acuity was 55.6 ± 18.5, 52.1 ± 22.3, 52.1 ± 22.6, 50.3 ± 23.8 and 47.8 ± 24.5 for 12, 24, 36, 48 and 60 months of treatment, respectively. Mean foveal center thickness was 209.7 ± 86.2, 190.6 ± 76.1, 174.7 ± 60.6, 189.8 ± 96.7 and 159.4 ± 73.3 for the same follow-up times. Baseline best corrected visual acuity was the only predictive factor for better visual outcome (p < 0.001). Discussion/Conclusion: Intravitreal anti-VEGF injections in patients with myopic choroidal neovascularization yielded a significant and sustained functional and anatomic improvement. Randomized long-term clinical trials are needed to determine the sustained efficacy of these drugs.

show abstract

Myopic choroidal neovascularization

Cited by 309 publications

References 24 publications

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

Contact Info

Product

Resources

About